18F-FDG PET/CT
Overview
Whole-body 18F-fluorodeoxyglucose (FDG) positron emission tomography combined with computed tomography (PET/CT). FDG uptake in tumor tissue reflects glucose metabolism; CT provides anatomical co-registration and attenuation correction. FDG PET/CT is used preoperatively for staging, post-treatment response assessment, and as a data layer in radiogenomic studies linking metabolic imaging phenotypes to molecular biomarkers. See also pet-ct-imaging for the generic PET-CT acquisition modality.
Used by
- PMID:30325352 — FDG PET/CT acquired in 201 of 211 NSCLC subjects in the nsclc-radiogenomics-stanford dataset; CT-based attenuation correction with iterative OSEM reconstruction; FDG dose 138.90–572.25 MBq (mean 309.26 MBq); uptake time 23.08–128.90 min (mean 66.58 min); tumor segmentations on co-registered CT were used for semantic annotation by one experienced radiologist PMID:30325352.
- Pre-SBRT FDG-PET/CT parameters (SUVmax, metabolic tumour volume, total lesion glycolysis) correlate with progression-free and overall survival in locally advanced pancreatic cancer, supporting their use in patient selection for SBRT. PMID:27826200
- FDG PET/CT response criteria (modified PERCIST v1.0) used as primary endpoint assessment for SUMMIT basket-trial patients with ERBB2/ERBB3-mutant solid tumors not evaluable by RECIST v1.1 PMID:29420467
Notes
- PET/CT variability (FDG dose, uptake time, scanner model) in the NSCLC radiogenomics dataset was not harmonized; this heterogeneity is flagged by the authors as a limitation for radiomic analyses across the dataset PMID:30325352.
- FDG PET/CT is also used in the tcia-hnscc collection for HNSCC patients (see pet-ct-imaging).
Sources
This page was processed by crosslinker on 2026-05-04. - PMID:27826200
This page was processed by entity-page-writer on 2026-05-15. - PMID:29420467
This page was processed by wiki-cli on 2026-05-15.